Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 763.15B |
| Revenue (ttm) | 47.38B |
| Net Income (ttm) | 14.68B |
| Shares Out | n/a |
| EPS (ttm) | 16.30 |
| PE Ratio | 51.98 |
| Forward PE | 34.17 |
| Dividend | 5.01 (0.60%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | n/a |
| Average Volume | 32 |
| Open | n/a |
| Previous Close | 840.00 |
| Day's Range | n/a |
| 52-Week Range | 538.08 - 880.00 |
| Beta | 0.33 |
| RSI | 60.60 |
| Earnings Date | Feb 6, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Better Buy in 2026: UnitedHealth Group or Eli Lilly?
These industry titans have gone in opposite directions this year; is that likely to change?
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.45% change from its previous close.
Thursday's Final Takeaways: Tech's Comeback & LLY Oral GLP-1 Drug
From Micron (MU) leading a strong comeback in tech, to Eli Lilly's (LLY) developments on an oral GLP-1 drug, Marley Kayden and Sam Vadas turn to headlines that caught their attention in Thursday's reb...
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound.
Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company's injection Zepbound and Nov...
Obesity pill race heats up
CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from ...
Obesity pill race heats up
CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from ...
Eli Lilly (LLY) Reports Promising Weight Maintenance Results for Orforglipron
Eli Lilly (LLY) Reports Promising Weight Maintenance Results for Orforglipron
Worried About the Stock Market in 2026? These 3 Stocks Did Well During the Last Bear Market.
Invest in stocks with good fundamentals, solid growth prospects, and steady dividends. These blue chip stocks have strong businesses that generate consistently strong results.
Why Eli Lilly shares should be higher — plus, our wishlist for Nike's earnings
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Lose Weight on Zepbound, Keep It Off With Eli Lilly's New Pill? Data Say That Works.
Eli Lilly has a new pill, called orforglipron, it plans to launch next year.
Eli Lilly (LLY) Reports Positive Phase 3 Trial Results, Impact on Obesity Treatment
Eli Lilly (LLY) Reports Positive Phase 3 Trial Results, Impact on Obesity Treatment
Better Buy in 2026: Pfizer or Eli Lilly?
These two stocks have been going in opposite directions over the past few years.
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss
The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medicatio...
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss
The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medicatio...
3 Momentum Stocks That Could Continue Their Strong Run in 2026
AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.
Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study
Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.
A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound.
Eli Lilly and Novo Nordisk file their new weight-loss drugs with the FDA.
Guru Fundamental Report for LLY
Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our Multi-Factor Investor model based on the published strategy of P...
Eli Lilly's (LLY) Orforglipron Shows Promising Results in Weight Maintenance Trial
Eli Lilly's (LLY) Orforglipron Shows Promising Results in Weight Maintenance Trial
Eli Lilly's Orforglipron Shows Positive Data In Phase 3 ATTAIN-MAINTAIN Trial
(RTTNews) - Eli Lilly and Company (LLY), Thursday announced positive topline results from the Phase 3 ATTAIN-MAINTAIN trial, which evaluated orforglipron for weight maintenance in participants who wer...
Eli Lilly (LLY) Reveals Promising Results for Orforglipron in Weight Maintenance Trial
Eli Lilly (LLY) Reveals Promising Results for Orforglipron in Weight Maintenance Trial
Eli Lilly obesity pill offers superior weight maintenance after injectable GLP-1s
Eli Lilly Scores Another Major Win: Time to Buy?
The company is running circles around its competition.
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switch...